Related Experiment Videos
Therapeutic advances in ankylosing spondylitis
1Department of Rheumatology, University Hospital Jean Minjoz, Boulevard A. Fleming, F-25030 Besançon, France. eric.toussirot@ufc-chu.univ-fcomte.fr
Expert Opinion on Investigational Drugs
|December 16, 2000
Summary
Ankylosing spondylitis (AS) management requires new treatments for refractory cases. Promising results are seen with TNF-alpha inhibitors, but further research is needed for long-term efficacy and safety.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Ankylosing spondylitis (AS) is a systemic inflammatory disease affecting the spine and sacroiliac joints.
- AS causes back pain, stiffness, and functional impairment with significant socio-economic impact.
- Current management includes lifestyle changes, NSAIDs, and sulfasalazine for peripheral arthritis, often insufficient for severe or refractory cases.
Purpose of the Study:
- To review current and emerging treatment options for ankylosing spondylitis.
- To highlight the need for innovative therapies in managing refractory AS.
- To assess the potential of new drug classes, including COX-2 inhibitors and TNF-alpha inhibitors.
Main Methods:
- Review of existing literature on AS management.
- Analysis of current treatment guidelines and clinical trial data.
- Evaluation of novel therapeutic agents and their preliminary outcomes.
Main Results:
- Conventional NSAIDs and sulfasalazine have limitations in controlling severe or refractory AS.
- COX-2 specific inhibitors may offer improved tolerability over traditional NSAIDs.
- TNF-alpha inhibitors (thalidomide, infliximab) show promise for severe/refractory AS, requiring further study.
Conclusions:
- Ankylosing spondylitis necessitates the development of novel and effective treatments.
- TNF-alpha targeting therapies represent a significant advancement for severe and refractory AS patients.
- Long-term efficacy and safety data for new agents like TNF-alpha inhibitors are crucial.